摘要
目的探讨哌罗匹隆联合奥氮平治疗难治性精神分裂症的临床疗效。方法选取2020年7月至2021年12月本院收治的100例难治性精神分裂症患者作为研究对象,采用随机数字表法分为两组,每组50例。对照组给予常规奥氮平治疗,研究组给予哌罗匹隆联合奥氮平治疗,比较两组治疗前后阳性和阴性症状量表(PANSS)评分、临床疗效及不良反应发生率。结果治疗后,两组一般精神病理症状、阳性症状、阴性症状评分均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05)。研究组治疗总有效率为94.00%,明显高于对照组的78.00%(P<0.05)。研究组不良反应发生率为8.00%,明显低于对照组的24.00%(P<0.05)。结论哌罗匹隆联合奥氮平治疗难治性精神分裂症疗效显著,能有效改善患者的临床症状,减少不良反应的发生,值得临床推广应用。
Objective To investigate the clinical efficacy of perospirone combined with olanzapine in the treatment of refractory schizophrenia.Methods A total of 100 patients with refractory schizophrenia admitted to our hospital from July 2020 to December 2021 were selected as the research subjects,and they were divided into two groups according to random number table,with 50 cases in each group.The control group was given conventional olanzapine treatment,and the study group was given piperopiron combined with olanzapine treatment,the positive and negative symptom scale(PANSS)score before and after treatment,clinical efficacy and incidence of adverse reactions were compared between the two groups.Results After treatment,the scores of general psychopathological symptoms,positive symptoms and negative symptoms in the two groups were lower than those before treatment,and the study group was lower than those in the control group,the difference was statistically significant(P<0.05).The total effective rate of in the study group was 94.00%,which was significantly higher than 78.00%in the control group(P<0.05).The incidence of adverse reactions in the study group was 8.00%,which was significantly lower than 24.00%in the control group(P<0.05).Conclusion Perospirone combined with olanzapine has a significant curative effect in the treatment of refractory schizophrenia,it can effectively improve the symptoms of patients and reduce the occurrence of adverse reactions,which is worthy of clinical application.
作者
魏利群
沈如瑾
江慎辉
WEI Liqun;SHEN Rujin;JIANG Shenhui(The Second Department of Psychiatry,the Fourth People's Hospital of Jingdezhen,Jingdezhen,Jiangxi,333000,China;The First Department of Psychiatry,the Fourth People's Hospital of Jingdezhen,Jingdezhen,Jiangxi,333000,China)
出处
《当代医学》
2022年第14期109-112,共4页
Contemporary Medicine
基金
江西省卫生健康委科技计划项目(202140417)。
